Company intelligence / Profile preview
FerruMax Pharmaceuticals, Inc.
Boston / general Massachusetts area [2][1], Massachusetts, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
FerruMax Pharmaceuticals developed FMX-8, a recombinant fusion protein targeting hepcidin to treat anemia of chronic disease. The company advanced FMX-8 through early clinical trials including Phase I and II studies in both healthy volunteers and patients with anemia due to chronic kidney disease. However, all development was discontinued after termination of the Phase II trial; no recent reports or ongoing programs are available[4][1].
- Therapeutic areas
- Hematology
- Modalities
- Recombinant fusion proteinsSmall molecules (possible, but primary focus is on fusion proteins)
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on FerruMax Pharmaceuticals, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FerruMax Pharmaceuticals, Inc..